The Biosimilar Medicines Group is a sector group of Medicines for Europe and represents the leading companies developing, manufacturing and marketing biosimilar medicines across Europe. Our member companies bring competition to the biologic medicines market, thereby increasing access to highly innovative medical treatments to patients in Europe and around the world, and supporting the sustainability of the European healthcare systems.
The vision of Medicines for Europe is to provide sustainable access to high quality medicines for all patients, based on 5 important pillars: patients, quality, value, sustainability and partnership.
The Biosimilar Medicines Group is open to all companies actively engaged in the biosimilar medicines sector in Europe.
MISSION: To inform the scientific, regulatory and general policy environment enabling broader patient access to modern therapies, ensuring the long-term sustainability of the biosimilar medicines industry through a high standard, safe and effective development process, a robust and predictable regulatory framework, continued investment and innovation in biosimilar medicines as well as the creation of competition in the biologic medicines sector.
VISION: To provide access to high quality biologic medicines to patients in Europe and worldwide.
Medicines for Europe is the official trade association for the European generic, biosimilar and value-added pharmaceutical industries, representing, supporting and developing our common scientific and technical interests within the European Union, Europe as a whole as well as between the European Union and third countries
Medicines for Europe provides many benefits to its members. We represent the voice of our members at European level on all matters affecting our industries.
For more information on how to become a member of Medicines for Europe, please click here.